Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid
-
Published:2023-09-20
Issue:18
Volume:24
Page:14345
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Ciobanu George Adrian12, Mogoantă Laurențiu3, Popescu Sanda Mihaela1ORCID, Ionescu Mihaela4, Munteanu Cristina Maria5, Staicu Ionela Elisabeta6, Mercuț Răzvan7, Georgescu Cristian Corneliu8, Scrieciu Monica9, Vlad Daniel2, Camen Adrian5
Affiliation:
1. Department of Oral Rehabilitation, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 2. Department of Oral and Maxillofacial Surgery, Dental Medicine Faculty, Ovidius University of Constanța, 900470 Constanța, Romania 3. Department of Histology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 4. Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 5. Department of Oral and Maxillofacial Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 6. Department of Orthodontics, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 7. Department of Plastic Surgery, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 8. Department of Pharmacology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania 9. Department of Prosthetic Dentistry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Abstract
Impairment of the immune response in MRONJ (medication-related osteonecrosis of the jaws) is one of the still unclear etiopathogenic mechanisms of this condition encountered in cancer patients treated with bisphosphonates, with negative effects on the patient’s quality of life. The aim of the present study was to correlate the immune response with etiopathogenic factors via immunohistochemical evaluation of the maxillary tissues in zoledronic acid osteonecrosis. The retrospective study included a group of 51 patients with various types of cancers, diagnosed with stage 2 or 3 MRONJ at zoledronic acid and treated surgically. Immunohistochemical expressions of αSMA, CD3, CD4, CD8, CD20, CD79α, CD68, CD204, and tryptase were evaluated. Immunohistochemical markers expressions were statistically analyzed according to the duration of the treatment, the trigger factor, the location of the MRONJ, and the healing status. Analysis of the immune response included T lymphocytes, B lymphocytes, plasma cells, macrophages, and mast cells. The duration of treatment significantly influenced the immunohistochemical expression of most markers (p < 0.05). For an increasing trend in treatment duration, a decreasing trend in marker score was observed, suggesting an inverse correlation. The expression of the markers was different depending on the trigger factor, on MRONJ localization (maxilla/mandible), and the healing status, being more intense in patients cured per primam compared to those who had relapses. The patient’s immune response was negatively influenced by the duration of the treatment, the trigger factor, the location of the lesion in the mandible, and the recurrence of MRONJ.
Funder
University of Medicine and Pharmacy of Craiova
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference103 articles.
1. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update;Ruggiero;J. Oral Maxillofac. Surg.,2022 2. One changing and challenging scenario: The treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ);Fusco;Support. Care Cancer,2022 3. Campisi, G., Mauceri, R., Bertoldo, F., Bettini, G., Biasotto, M., Colella, G., Consolo, U., Di Fede, O., Favia, G., and Fusco, V. (2020). Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020. Int. J. Environ. Res. Public Health, 17. 4. Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: Surgery or conservative therapy?;Sacco;Br. J. Oral Maxillofac. Surg.,2022 5. Rosales, H.D., Guevara, H.G., Requejo, S., Jensen, M.D., Acero, J., and Olate, S. (2023). Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients—A Systematic Review. J. Clin. Med., 12.
|
|